Influenza is a highly contagious, acute respiratory illness with a long history of outbreaks dating back several centuries. Although immunization is an effective means of protection against influenza, vaccination rates have been suboptimal, especially among certain high-risk groups, including children and health care personnel. This article reviews basic information about influenza and immunization, discusses the relevance of children as vectors of disease, and highlights current information on FluMist, an intranasally administered, live attenuated influenza vaccine, including studies of its use compared with trivalent inactivated vaccine and in children.
Get the basic information about influenza and immunization, including current information on FluMist and its use in children.
Michele Michael is a program director in advanced practice pediatrics, Elizabeth Helm is a clinical instructor, and Brigit Van Graafeiland is an assistant professor at the University of Maryland School of Nursing, Baltimore, MD. Frank Malinoski is a senior vice president at MedImmune, Gaithersburg, MD, the manufacturer of FluMist, the product discussed in this article. Jay Bauman is president of Scientific and Technical Evaluation of Pharmaceuticals, Raleigh, NC, and a former employee of MedImmune and serves currently as an advisor to and provides medical writing support to the company; he was paid by MedImmune for his work on this and other manuscripts on the company's products. Michael, Helm, and VanGraafeil consulted MedImmune in the writing of this article; MedImmune reviewed the content prior to submission and made changes to several drafts but did not pay those three authors for their work. MedImmune also reviewed the article and made changes during the editing process.
Contact author: Michele Michael, email@example.com.